Related Experiment Video
Updated: Jul 4, 2026
09:06
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
[Fighting heart attacks and atherosclerosis: a therapeutical challenge]
P-F Keller1, Vincent Barthassat, F Scherrer-Burri
1Service de cardiologie, HUG, 1211 Geneve 14.
Revue Medicale Suisse
|July 3, 2008
Summary
Improving patient education during hospitalization for myocardial infarction is key to reducing recurrent cardiovascular events. Utilizing therapeutic education and motivational interviews can enhance patient adherence to treatment plans.
Area of Science:
- Cardiology
- Public Health
- Patient Education
Context:
- Myocardial infarction (MI) is a significant complication of atherosclerosis.
- While treatments have improved outcomes and reduced hospital stays, cardiovascular event recurrence remains a challenge.
Purpose:
- To explore the role of therapeutic education and motivational interviewing in improving patient adherence to treatment post-MI.
- To identify strategies for enhancing patient information delivery during initial hospitalization.
Summary:
- Effective management of MI requires addressing the chronic nature of atherosclerosis.
- Enhancing patient understanding and motivation during hospitalization is crucial for long-term adherence.
- Therapeutic education and motivational interviews are proposed as key tools to improve patient engagement with treatment plans.
Impact:
- Improved adherence to therapeutic regimens can significantly decrease the recurrence of cardiovascular events.
- Optimizing information delivery during hospitalization can lead to better long-term health outcomes for MI patients.
- This approach can reduce healthcare burdens associated with recurrent MI and cardiovascular disease.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...